Last updated on December 19th, 2024 at 09:30 pm
Current Price: ₹455.00 (latest available data)
Biocon Ltd., a leader in the biopharmaceutical industry, is one of India’s most prominent players in biotechnology, known for its innovative medicines, especially in the areas of oncology, diabetes, and immunology. In this article, we’ll explore Biocon’s stock price forecast from 2024 to 2040.
Biocon Ltd
About Biocon Ltd.
Biocon is an Indian global biopharmaceutical company founded by Kiran Mazumdar-Shaw in 1978. It specializes in biopharmaceuticals, including complex generic drugs, biosimilars, and novel drugs. The company has a strong presence in the oncology and diabetes sectors and is focusing on expanding its offerings in immunology and other high-demand therapeutic areas.
- Founded: 1978
- Headquarters: Bangalore, India
- Sector: Biopharmaceuticals, Biotechnology
- Key Areas: Oncology, Diabetes, Immunology, Biosimilars
- Market Presence: Global, with operations in over 120 countries
- Revenue: ₹10,000 crores (approx.) for FY 2023
- Employees: Over 11,000
Company Details
- CEO: Kiran Mazumdar-Shaw
- Market Cap: ₹83,000 Crores (approx.)
- Revenue: ₹10,000 Crores (FY 2023)
- Key Acquisitions: Biocon Biologics, Syngene International, and more
Promoter Details
Biocon has a strong promoter backing, with Kiran Mazumdar-Shaw holding a significant stake in the company. The company has attracted a variety of institutional investors, reflecting confidence in its growth prospects.
| Shareholder | Ownership (%) |
|---|---|
| Kiran Mazumdar-Shaw | 58.20% |
| Institutional Investors | 31.80% |
| Public Shareholders | 10% |
Biocon Ltd. Share Price Target 2024
Growth Drivers:
- Expansion in the biosimilars market, particularly in emerging markets.
- Strong pipeline in oncology and diabetes medications.
- Strategic partnerships for research and development.
- Focus on reducing the cost of key biosimilars to make them affordable globally.
- Minimum Target: ₹480
- Maximum Target: ₹520
Biocon Ltd. Share Price Target 2025
Key Factors:
- Revenue growth driven by increased biosimilars sales and global expansion.
- Commercialization of its proprietary drugs in international markets.
- Research and development advancements in immunotherapy and other therapeutic areas.
- Potential strategic alliances and collaborations with global pharma giants.
- Minimum Target: ₹550
- Maximum Target: ₹600
Biocon Ltd. Share Price Target 2026 to 2030
| Year | Minimum Target (INR) | Maximum Target (INR) |
|---|---|---|
| 2026 | ₹650 | ₹700 |
| 2027 | ₹750 | ₹800 |
| 2028 | ₹850 | ₹900 |
| 2029 | ₹950 | ₹1,000 |
| 2030 | ₹1,100 | ₹1,200 |
Biocon Ltd. Share Price Target 2035
Biocon’s long-term growth prospects will continue to be driven by its expanding pipeline of biosimilars and innovative medicines. The increasing global demand for affordable biotechnology solutions will provide strong tailwinds.
- Minimum Target: ₹1,500
- Maximum Target: ₹1,800
Biocon Ltd. Share Price Target 2040
In the long term, Biocon’s focus on cutting-edge treatments, such as immunotherapies, and its expansion in key international markets will likely lead to continued growth. With the global biotechnology market expected to grow substantially, Biocon is well-positioned to capitalize on these trends.
- Minimum Target: ₹2,500
- Maximum Target: ₹3,000
Final Thoughts
Biocon Ltd. is well-positioned to continue its growth trajectory, driven by a robust portfolio of biosimilars and oncology medications. The company’s ongoing commitment to research, global expansion, and cost-effective drug solutions should propel its stock price upward over the coming decades. While short-term market fluctuations may occur, the long-term outlook for Biocon remains positive.
Disclaimer: Stock market investments carry risks. Always conduct your own research or consult a financial advisor before making any investment decisions. For more insights, stay tuned to moneyphobia.in.
